Published in Lancet Neurol on February 01, 2006
AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol (2010) 3.28
AQP4 antibody-positive Thai cases: clinical features and diagnostic problems. Neurology (2011) 1.77
Treatment of neuromyelitis optica: current debate. Ther Adv Neurol Disord (2008) 0.95
Polymorphisms in the neuromyelitis optica auto-antigen AQP4 and susceptibility to multiple sclerosis. J Neurol (2007) 0.85
A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. J Neurol (2011) 0.83
CD58 polymorphisms associated with the risk of neuromyelitis optica in a Korean population. BMC Neurol (2014) 0.75
"OSMS is NMO, but not MS": confirmed by NMO-IgG? Lancet Neurol (2005) 1.54
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology (2014) 6.73
Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain (2007) 4.82
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain (2010) 4.77
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol (2009) 3.91
Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc (2007) 3.32
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26
Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol (2004) 2.91
Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. Arch Neurol (2008) 2.80
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol (2006) 2.67
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol (2008) 2.58
Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology (2013) 2.52
Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol (2012) 2.49
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol (2013) 2.46
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology (2013) 2.34
Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol (2003) 2.29
Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc (2004) 2.29
Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology (2003) 2.28
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26
Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol (2010) 2.26
Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 2.12
Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A (2011) 2.11
Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol (2013) 2.10
Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc (2003) 2.09
Experimental autoimmune autonomic neuropathy. J Neurophysiol (2003) 2.02
Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology (2012) 2.00
The spectrum of autoimmune autonomic neuropathies. Ann Neurol (2003) 1.93
Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc (2010) 1.85
An approach to the diagnosis of acute transverse myelitis. Semin Neurol (2008) 1.80
Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol (2013) 1.79
Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol (2003) 1.79
Passive transfer of autoimmune autonomic neuropathy to mice. J Neurosci (2004) 1.78
Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol (2013) 1.78
Sleep manifestations of voltage-gated potassium channel complex autoimmunity. Arch Neurol (2011) 1.77
An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study. Lancet Neurol (2009) 1.73
Acute disseminated encephalomyelitis: current understanding and controversies. Semin Neurol (2008) 1.72
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain (2012) 1.65
The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve (2012) 1.65
Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol (2009) 1.61
Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol (2010) 1.60
The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol (2014) 1.60
Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol (2008) 1.59
Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol (2009) 1.55
Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol (2005) 1.51
Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion. Neurology (2012) 1.49
Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49
Reversible extralimbic paraneoplastic encephalopathies with large abnormalities on magnetic resonance images. Arch Neurol (2009) 1.48
Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc (2006) 1.46
Striational antibodies in a paraneoplastic context. Muscle Nerve (2013) 1.46
Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med (2006) 1.46
Familial inclusion body myositis: a report on two Japanese sisters. Intern Med (2003) 1.45
The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler (2011) 1.42
Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry (2012) 1.42
Pure optic-spinal form of multiple sclerosis in Japan. Brain (2002) 1.41
CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG. Neurology (2011) 1.41
Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol (2012) 1.40
Pseudopseudoseizures: conditions that may mimic psychogenic non-epileptic seizures. Psychosomatics (2011) 1.39
Neuromyelitis optica: changing concepts. J Neuroimmunol (2007) 1.39
Bright red nuclei. Neurology (2004) 1.38
Idiopathic autonomic neuropathy: comparison of cases seropositive and seronegative for ganglionic acetylcholine receptor antibody. Arch Neurol (2004) 1.38